Christoph U. Correll, MD

Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Hempstead, New York; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany

Original Research

National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression

May 15, 2014

Mark Olfson, Christoph U. Correll, Tobias Gerhard, et al

ASCP Corner

The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches

March 15, 2014

Christoph U. Correll, Swapnil Gupta, John D. Cahill, et al

Commentary

Schizophrenia: Mechanism of Action of Current and Novel Treatments

March 7, 2014

John M. Kane, Christoph U. Correll

Meta-Analysis

Antipsychotics for Cocaine or Psychostimulant Dependence: Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials

December 15, 2013

Christoph U. Correll, Taro Kishi, Yuki Matsuda, et al

ASCP Corner

Decision Making and Antipsychotic Medication Treatment for Youth With Autism Spectrum Disorders: Applying Guidelines in the Real World

October 15, 2013

Christoph U. Correll, Stephanie H. Ameis, Patricia Corbett-Dick, et al

Meta-Analysis

Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies

October 15, 2013

John M. Kane, Christoph U. Correll, Taishiro Kishimoto, et al

Educational Activity

Addressing Barriers to Using Long-Acting Injectable Antipsychotics and Appropriately Monitoring Antipsychotic Adverse Effects

August 15, 2013

Christoph U. Correll

Meta-Analysis

Antipsychotics for Primary Alcohol Dependence: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials

July 15, 2013

Christoph U. Correll, Taro Kishi, Serge Sevy, et al

Article

Termination of Clozapine Treatment Due to Medical Reasons: When Is It Warranted and How Can It Be Avoided?

June 15, 2013

John M. Kane, Christoph U. Correll, Peter Manu, et al

Educational Activity

The Prevalence of Negative Symptoms in Schizophrenia and Their Impact on Patient Functioning and Course of Illness

February 15, 2013

Christoph U. Correll

InfoPack

How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study

August 15, 2012

Christoph U. Correll, Ashok Malla, Jonathan M. Meyer, et al

Review Article

Are Antipsychotics Effective for the Treatment of Anorexia Nervosa? Results From a Systematic Review and Meta-Analysis

June 15, 2012

Christoph U. Correll, Taro Kishi, Vivian Kafantaris, et al

« 1 … 6 7 8 9 10 11 »

Christoph U. Correll, MD

National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression

The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches

Schizophrenia: Mechanism of Action of Current and Novel Treatments

Antipsychotics for Cocaine or Psychostimulant Dependence: Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials

Decision Making and Antipsychotic Medication Treatment for Youth With Autism Spectrum Disorders: Applying Guidelines in the Real World

Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies

Addressing Barriers to Using Long-Acting Injectable Antipsychotics and Appropriately Monitoring Antipsychotic Adverse Effects

Antipsychotics for Primary Alcohol Dependence: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials

Termination of Clozapine Treatment Due to Medical Reasons: When Is It Warranted and How Can It Be Avoided?

The Prevalence of Negative Symptoms in Schizophrenia and Their Impact on Patient Functioning and Course of Illness

How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study

Are Antipsychotics Effective for the Treatment of Anorexia Nervosa? Results From a Systematic Review and Meta-Analysis

ELSEWHERE:

FOLLOW US:

Christoph U. Correll, MD

National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression

The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches

Schizophrenia: Mechanism of Action of Current and Novel Treatments

Antipsychotics for Cocaine or Psychostimulant Dependence: Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials

Decision Making and Antipsychotic Medication Treatment for Youth With Autism Spectrum Disorders: Applying Guidelines in the Real World

Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies

Addressing Barriers to Using Long-Acting Injectable Antipsychotics and Appropriately Monitoring Antipsychotic Adverse Effects

Antipsychotics for Primary Alcohol Dependence: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials

Termination of Clozapine Treatment Due to Medical Reasons: When Is It Warranted and How Can It Be Avoided?

The Prevalence of Negative Symptoms in Schizophrenia and Their Impact on Patient Functioning and Course of Illness

How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study

Are Antipsychotics Effective for the Treatment of Anorexia Nervosa? Results From a Systematic Review and Meta-Analysis

Insightful. Evidence-based. Human-centered.

Subscribe to readmore articles

Subscribe to read
more articles